Advancements In the Management of Adult Acute Lymphoblastic Leukemia

The presentation will discuss the advancements witnessed over the years in the management of adult acute lymphoblastic leukemia (ALL) in terms of a broad and integrated biologic work-up at presentation, a biologically-based prognostic stratification and the current treatment scenarios. The use of pediatric-inspired protocols will be discussed, not only for very young adults, as well as the revolutionary changes witnessed in the management of Ph+ ALL patients of all ages following the advent of tyrosine kinase inhibitors, and the role and impact that minimal residual disease monitoring plays today for an optimal clinical management. The clinical use today of monoclonal antibodies for the treatment of B-lineage ALL will be discussed, as well as the developments of CAR-T cell therapy. Finally, the possibility of recognizing new ALL subentities – such as Ph-like ALL and early-T precursor ALL – through the use of always more advanced technologies will also be covered.